Considering selection bias when developing a search strategy

Archives of Internal Medicine

Volumn 171, Issue 5, 2011, Pages 471-472

  Nakao, Yoko M ^a   Ueshima, Kenji ^a   Teramukai, Satoshi ^b   Tanaka, Sachiko ^a   Yasuno, Shinji ^a   Fujimoto, Akira ^a   Kawakami, Koji ^a   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CANDESARTAN; DIURETIC AGENT; RENIN INHIBITOR;

ANTIHYPERTENSIVE THERAPY; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; HYPERTENSION; LETTER; MEDICAL RESEARCH; META ANALYSIS (TOPIC); METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC);

CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; SEARCH ENGINE; SELECTION BIAS;

EID: 79952592380     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.45     Document Type: Letter

References (5)

1. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk [published online November 8, 2010]. Arch Intern Med. 2011;171(5):384-394.
2. Ogihara T, Nakao K, Fukui T, et al; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan comparedwith amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51(2):393-398. (Pubitemid 351159955)
3. Sawada T, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009;30(20):2461-2469.
4. Kasanuki H, Hagiwara N, Hosoda S, et al; HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J. 2009;30(10):1203-1212.
5. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and reninangiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. 2009;30(6):679-688.